1,1-dimethylethyl (2R,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-{[(methylsulfonyl)oxy]methyl}-1-pyrrolidinecarboxylate | 924907-62-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1,1-dimethylethyl (2R,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-{[(methylsulfonyl)oxy]methyl}-1-pyrrolidinecarboxylate
• 英文别名: 1-tert-butyloxycarbonyl-(2R,4S)-2-(methylsulfonyloxymethyl)-4-(tert-butyldimethylsilyloxy)pyrrolidine；tert-butyl (2R,4S)-4-[tert-butyl(dimethyl)silyl]oxy-2-(methylsulfonyloxymethyl)pyrrolidine-1-carboxylate
• CAS: 924907-62-0
• 化学式: C₁₇H₃₅NO₆SSi
• 分子量: 409.62
• InChiKey: NPAHVNPWHLQLNI-KGLIPLIRSA-N

物化性质

• 沸点：
  463.2±30.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.36
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  90.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl (2R,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-{[(methylsulfonyl)oxy]methyl}-1-pyrrolidinecarboxylate 在 四丁基氟化铵 、 三乙基硼氢化锂 作用下， 以 四氢呋喃 为溶剂， 生成 (2S,4s)-4-羟基-2-甲基-吡咯烷-1-羧酸叔丁酯
  参考文献：
  名称：

  Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C

  摘要：

  The discovery of potent and selective cyanamide-based inhibitors of the cysteine protease cathepsin C is detailed. Optimization of the template with regard to plasma stability led to the identification of compound 17, a potent cathepsin C inhibitor with excellent selectivity over other cathepsins and potent in vivo activity in a cigarette smoke mouse model.

  DOI：

  10.1021/ml100212k
• 作为产物：
  描述：

  (2R,4S)-methyl 4-hydroxypyrrolidine-2-carboxylate 在 咪唑 、 锂硼氢 、 三乙胺 作用下， 生成 1,1-dimethylethyl (2R,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-{[(methylsulfonyl)oxy]methyl}-1-pyrrolidinecarboxylate
  参考文献：
  名称：

  Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C

  摘要：

  The discovery of potent and selective cyanamide-based inhibitors of the cysteine protease cathepsin C is detailed. Optimization of the template with regard to plasma stability led to the identification of compound 17, a potent cathepsin C inhibitor with excellent selectivity over other cathepsins and potent in vivo activity in a cigarette smoke mouse model.

  DOI：

  10.1021/ml100212k

文献信息

• [EN] NOVEL CATHEPSIN C INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE LA CATHEPSINE C ET LEUR UTILISATION
  申请人：GLAXO GROUP LTD

  公开号：WO2009026197A1

  公开（公告）日：2009-02-26

  The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD.

  这项发明涉及到符合以下式（I）的化合物，其中R1、R2a、R2b、R2c、R3和n的定义如下，并且其药用盐。它们是半胱氨酸蛋白酶C抑制剂，可用于治疗由半胱氨酸蛋白酶C酶介导的疾病，如慢性阻塞性肺病。
• ADENINE DERIVATIVES
  申请人：Buchstaller Hans-Peter

  公开号：US20100160352A1

  公开（公告）日：2010-06-24

  Novel adenine derivatives of the formula (I), in which R 1 , R 2 , R 3 , X and Y have the meanings indicated in Claim 1 , are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  新型腺嘌呤衍生物的化学式（I），其中R1、R2、R3、X和Y具有权利要求1中指示的含义，是HSP90抑制剂，可用于制备用于治疗需要HSP90抑制、调节和/或调控的疾病的药物。
• NOVEL CATHEPSIN C INHIBITORS AND THEIR USE
  申请人：Palovich Michael R.

  公开号：US20090264431A1

  公开（公告）日：2009-10-22

  The invention is directed to compounds according to Formula I: wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD.

  本发明涉及符合以下式子I的化合物：其中R1、R2a、R2b、R2c、R3和n的定义如下，以及其药学上可接受的盐。它们是卡特普西林C抑制剂，可用于治疗由卡特普西林C酶介导的疾病，如COPD。
• Adenine derivatives
  申请人：Merck Patent Gesellschaft mit beschrankter Haftung

  公开号：US07977343B2

  公开（公告）日：2011-07-12

  Novel adenine derivatives of the formula (I), in which R1, R2, R3, X and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  公式(I)的新腺嘌呤衍生物，其中R1，R2，R3，X和Y具有声明1中指示的含义，是HSP90抑制剂，并可用于制备用于治疗HSP90的抑制，调节和/或调节在其中发挥作用的疾病的药物。
• HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2752410B1

  公开（公告）日：2016-08-31